David Amsellem
Stock Analyst at Piper Sandler
(4.70)
# 131
Out of 5,182 analysts
174
Total ratings
62.86%
Success rate
21.69%
Average return
Main Sectors:
Stocks Rated by David Amsellem
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| OGN Organon & Co. | Upgrades: Neutral | $5 → $14 | $13.33 | +5.07% | 7 | Apr 28, 2026 | |
| ABBV AbbVie | Maintains: Overweight | $299 → $294 | $199.39 | +47.45% | 5 | Apr 23, 2026 | |
| BIIB Biogen | Upgrades: Overweight | $177 → $214 | $187.50 | +14.13% | 5 | Apr 14, 2026 | |
| DFTX Definium Therapeutics | Initiates: Overweight | $49 | $20.87 | +134.79% | 1 | Apr 10, 2026 | |
| ALKS Alkermes | Maintains: Overweight | $45 → $43 | $33.99 | +26.51% | 9 | Mar 24, 2026 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Overweight | $219 → $232 | $202.09 | +14.80% | 16 | Mar 19, 2026 | |
| TEVA Teva Pharmaceutical Industries | Reiterates: Overweight | $40 → $41 | $35.13 | +16.71% | 12 | Mar 4, 2026 | |
| PTHS Pelthos Therapeutics | Initiates: Overweight | $48 | $24.92 | +92.62% | 1 | Feb 27, 2026 | |
| BMY Bristol-Myers Squibb Company | Maintains: Overweight | $66 → $75 | $57.67 | +30.05% | 3 | Feb 23, 2026 | |
| AMGN Amgen | Maintains: Overweight | $381 → $432 | $334.00 | +29.34% | 7 | Feb 18, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $9 → $12 | $14.98 | -19.89% | 8 | Jan 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $148 → $223 | $183.60 | +21.46% | 4 | Jan 16, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $18 | $6.34 | +183.99% | 1 | Jan 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $9 | $1.90 | +373.68% | 1 | Nov 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $5 → $8 | $4.07 | +96.56% | 2 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $6 → $8 | $5.99 | +33.56% | 6 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $11 → $13 | $12.71 | +2.28% | 5 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $175 → $179 | $128.75 | +39.03% | 12 | Oct 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $40 → $65 | $47.72 | +36.21% | 17 | Oct 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $30 → $25 | $21.60 | +15.77% | 9 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $131 → $121 | $47.26 | +156.03% | 8 | Aug 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $36 → $37 | $33.18 | +11.51% | 8 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $15 → $9 | $9.60 | -6.25% | 3 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $68 | $78.19 | -13.03% | 1 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $9 → $3 | $5.55 | -45.95% | 7 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $42 | $25.09 | +67.40% | 10 | Jul 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $20 → $21 | $4.14 | +407.25% | 3 | Feb 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $72 → $42 | $30.94 | +35.75% | 3 | Oct 16, 2023 |
Organon & Co.
Apr 28, 2026
Upgrades: Neutral
Price Target: $5 → $14
Current: $13.33
Upside: +5.07%
AbbVie
Apr 23, 2026
Maintains: Overweight
Price Target: $299 → $294
Current: $199.39
Upside: +47.45%
Biogen
Apr 14, 2026
Upgrades: Overweight
Price Target: $177 → $214
Current: $187.50
Upside: +14.13%
Definium Therapeutics
Apr 10, 2026
Initiates: Overweight
Price Target: $49
Current: $20.87
Upside: +134.79%
Alkermes
Mar 24, 2026
Maintains: Overweight
Price Target: $45 → $43
Current: $33.99
Upside: +26.51%
Jazz Pharmaceuticals
Mar 19, 2026
Maintains: Overweight
Price Target: $219 → $232
Current: $202.09
Upside: +14.80%
Teva Pharmaceutical Industries
Mar 4, 2026
Reiterates: Overweight
Price Target: $40 → $41
Current: $35.13
Upside: +16.71%
Pelthos Therapeutics
Feb 27, 2026
Initiates: Overweight
Price Target: $48
Current: $24.92
Upside: +92.62%
Bristol-Myers Squibb Company
Feb 23, 2026
Maintains: Overweight
Price Target: $66 → $75
Current: $57.67
Upside: +30.05%
Amgen
Feb 18, 2026
Maintains: Overweight
Price Target: $381 → $432
Current: $334.00
Upside: +29.34%
Jan 28, 2026
Maintains: Neutral
Price Target: $9 → $12
Current: $14.98
Upside: -19.89%
Jan 16, 2026
Maintains: Overweight
Price Target: $148 → $223
Current: $183.60
Upside: +21.46%
Jan 9, 2026
Initiates: Overweight
Price Target: $18
Current: $6.34
Upside: +183.99%
Nov 25, 2025
Initiates: Overweight
Price Target: $9
Current: $1.90
Upside: +373.68%
Nov 7, 2025
Maintains: Overweight
Price Target: $5 → $8
Current: $4.07
Upside: +96.56%
Nov 7, 2025
Maintains: Neutral
Price Target: $6 → $8
Current: $5.99
Upside: +33.56%
Oct 31, 2025
Reiterates: Overweight
Price Target: $11 → $13
Current: $12.71
Upside: +2.28%
Oct 29, 2025
Maintains: Overweight
Price Target: $175 → $179
Current: $128.75
Upside: +39.03%
Oct 9, 2025
Upgrades: Overweight
Price Target: $40 → $65
Current: $47.72
Upside: +36.21%
Aug 8, 2025
Maintains: Neutral
Price Target: $30 → $25
Current: $21.60
Upside: +15.77%
Aug 1, 2025
Maintains: Overweight
Price Target: $131 → $121
Current: $47.26
Upside: +156.03%
May 9, 2025
Reiterates: Neutral
Price Target: $36 → $37
Current: $33.18
Upside: +11.51%
Mar 21, 2025
Downgrades: Neutral
Price Target: $15 → $9
Current: $9.60
Upside: -6.25%
Oct 11, 2024
Initiates: Overweight
Price Target: $68
Current: $78.19
Upside: -13.03%
Aug 2, 2024
Downgrades: Underweight
Price Target: $9 → $3
Current: $5.55
Upside: -45.95%
Jul 3, 2024
Maintains: Overweight
Price Target: $42
Current: $25.09
Upside: +67.40%
Feb 16, 2024
Maintains: Overweight
Price Target: $20 → $21
Current: $4.14
Upside: +407.25%
Oct 16, 2023
Maintains: Overweight
Price Target: $72 → $42
Current: $30.94
Upside: +35.75%